Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

The industry's costly drug development failures are often attributed to clinical issues. However, the root cause is frequently organizational: siloed teams, misaligned incentives, and hierarchical leadership that stifle the knowledge sharing necessary for success.

Successful healthcare systems like Kaiser improve blood pressure control not through better individual doctors, but by implementing system-wide solutions: standardized treatment protocols, empowered care teams, and actionable data registries. This shifts the focus from individual effort to scalable processes.

The success of the U.S. clinical trial infrastructure is not abstract. According to the American Cancer Society, this system is directly responsible for saving over 4 million lives between 1995 and 2025. This quantifies the immense public health impact of systematic research, demonstrating that without trials, progress in reducing cancer mortality would stagnate.

Landmark discoveries, like EGFR mutations, didn't start in a lab but with astute oncologists noticing patterns in how some patients responded to treatment while others didn't. This highlights that every patient interaction is a research opportunity, offering clues that can lead to the next scientific breakthrough.

Dr. Abelson’s career spans the transformation of clinical research from an endeavor led by a single physician-scientist to a complex industry with specialized companies for statistics, patient recruitment, and regulatory affairs. This specialization has enabled the current rapid pace of drug development.

In oncology R&D, a successful two-drug combination isn't the final goal but the new standard of care to build upon. Researchers immediately begin planning for "triplets"—adding a third agent to the successful doublet—demonstrating a relentless, forward-looking strategy to incrementally improve patient outcomes.

The Innovative Genomics Institute is tackling rare diseases by creating a standardized platform. By keeping elements like the delivery vehicle and enzyme constant and only changing the guide RNA, they aim to create a repeatable 'bucket trial' process for developing hundreds of cures, not just one-offs.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.